Following the invitation Amniotics and the partners in the project will finalise the agreement with the EIC over the coming months. After agreement is signed, we expect to get the project started in Q1-2023 and it will continue for thirty-six months.

“We are delighted to be selected to receive the EIC-Pathfinder grant, which will support our AMNI-NK003 project in a real and substantive way,” says Marcus Larsson M.D., Ph.D., Chief Executive Officer of Amniotics AB. “Today there is a great need for treatments for patients with cancer, and off shelf allogeneic NK-cells has the potential to become an important tool to fight hematological malignancies and solid tumours. The Amniotics team and its partners have put together a robust plan to further our drug development activities and the recognition of the EIC lends us the credibility our programme warrants”.
The European Innovation Council (EIC) Pathfinder grants support research and consortia in investigating or developing emerging breakthrough technology to develop and scale-up game-changing innovations.
 
About AMNI-NK003
Amniotics anti-cancer program AMNI-NK003 aims to generate off-the-shelf Natural Killer (NK) cells from induced pluripotent stem cells (iPS) targeting hematological and solid cancers. NK cell therapy is a therapeutic approach that uses immune cells to attack tumours. The difficulty of producing NK cells in large volumes has resulted in high production costs, which has hampered progress. AMNI-NK003 is designed to produce NK cells, with high anti-tumour efficacy, efficiently and on a large scale.